Search company, investor...



Other Investors | Alive

About Ectopharma

EctoPharma is a company developing therapeutic pesticides for specific healthcare and veterinary markets, for conditions such as the treatment of human head lice.

Headquarters Location

40 Torphichen Street

United Kingdom

Missing: Ectopharma's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Ectopharma's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Ectopharma Patents

Ectopharma has filed 1 patent.

patents chart

Application Date

Grant Date


Related Topics




Insecticides, Acetylcholinesterase inhibitors, Amines, Diols, Dosage forms


Application Date


Grant Date



Related Topics

Insecticides, Acetylcholinesterase inhibitors, Amines, Diols, Dosage forms



Latest Ectopharma News


Jul 4, 2017

FIRST STAGE FUNDING FOR RYBOQUIN TRI Cap, the Borders-based angel syndicate, has participated in a first stage funding round valued at more than £250,000 for Ectopharma spin-out, Ryboquin Ltd, along with the Scottish Investment Bank and Strathtay Ventures. Ryboquin is a virtual life sciences company which aims to commercialise patented technologies in the area of human cancer medicine. Its first product is Ryboquin ECP-102, one of a new class of drugs designed to make chemotherapy more efficient. This first round of funding will take Ryboquin to the next funding stage of product development before a Phase 1 trial. Rob Dick, TRI Cap Chairman, commented: “TRI Cap members are please to be involved in this leading-edge life science company, which further establishes our syndicate’s presence in this sector. Our long association with Ectopharma created a perfect bridge to this deal and, working with colleagues from Strathtay Ventures and Scottish Investment Bank, we will be actively involved in supporting this exciting venture.”

Ectopharma Frequently Asked Questions (FAQ)

  • What is Ectopharma's latest funding round?

    Ectopharma's latest funding round is Other Investors.

  • Who are the investors of Ectopharma?

    Investors of Ectopharma include Braveheart, TRICAPITAL Angel Investors and Caledonia Investments.

  • Who are Ectopharma's competitors?

    Competitors of Ectopharma include Selecta Biosciences, Pozen, Provepep, iPierian, Topaz Pharmaceuticals and 10 more.

Compare Ectopharma to Competitors


Velbionanotech is designing drugs for various diseases such as Heart Disease, kidney stones, AIDS, Cancer, cosmetic generic products using a short fragment of DNA as a new type of drugs. These drugs are assembled in Nanochips and as nano particals for delivering in human body, which are affective in curing the sick/diseased and healing the injured. nVBN are working into New gene therapy procedures, DNA-based sensors, and other medical applications by using a new method developed to initiate and control chemical reactions on DNA strands. On the other hand silicon-based nanochips with itching and self-assembling techniques used to deliver drugs on the diseased molecules. The company are designing bionano products for the treatment of various diseases for Kidney stones,Gallbladder,Liver, Lungs,Heart etc mixing biology with traditional machinery. VBN Nanomedicine prepared for Heart disease, Galbladder, Liver, Kidney stones will have no side effect and it is safe to use since it is herbal. nn

Traversa Therapeutics

Traversa Therapeutics is a biopharmaceutical company engaged in the discovery, development and commercialization of RNAi anti-cancer therapeutics. The company strives to rapidly advance short interfering RNA (siRNA) platform delivery technologies for use by RNAi therapeutic companies in targeting a variety of acute, chronic and infectious human diseases. Traversa is focused on the optimization of platform delivery technology, as well as advancement of therapeutic programs for the treatment of leukemia and glioblastoma.


The company are developing siRNA drugs targeting a control factor for HIF (hypoxia-inducible factor), which is one of the main factors involved in angiogenesis. The company have found that siRNA can promote angiogenesis by inducing expression of several angiogenic factors simultaneously by preventing breakdown of HIF inside the cell. It is therefore expected that delivery of siRNA to disease-affected sites can efficiently induce angiogenesis, leading to a in treatment for obstructive arteriosclerosis.

Esperance Pharmaceuticals

Esperance Pharmaceuticals develops targeted anticancer drugs that selectively kill cancer cells without harming normal cells.

Actinobac Biomed

Actinobac Biomed is a biopharmaceutical company developing therapeutics for multiple indications, including blood cancers, autoimmune/inflammatory diseases, and HIV. Its drug candidates are based upon Leukothera (LtxA), a natural protein that targets and eliminates white blood cells (WBCs) involved in the mechanism of many diseases. Products based upon Leukothera are being developed by Actinobac for the treatment of leukemia/lymphoma, dry eye, and psoriasis.

Synapsin Pharmaceuticals

SYNAPSIN is developing therapeutic strategies for the treatmentand prevention ofneurodegenerative disorders such as Alzheimer's disease (AD),Parkinson's disease, Amyotrophic Lateral Sclerosis (ALS), and spinal cord injury.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.